Candid Therapeutics Acquired by UCB | Healthcare M&A Deal

UCB has completed the acquisition of Candid Therapeutics, a pharmaceuticals business in Belgium, for $2.2B. UCB acquires Candid Therapeutics to expand its autoimmune drug pipeline with bispecific antibody therapeutics designed to drive long remissions by targeting malfunctioning B cells. Candid Therapeutics is developing bispecifics and related immune reset approaches for immunological conditions, aligning with UCB’s focus on next-wave biologics in healthcare M&A. The UCB acquisitions are structured as a strategic acquisition and platform acquisition, with $2.0B upfront cash and up to $200M in milestone payments. The deal is announced and is expected to close by the end of Q2 2026 or shortly thereafter.